ArticleThe New England journal of medicine2022
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.
Article in The New England journal of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.Nature communications · 2024Trial
- Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.Journal for immunotherapy of cancer · 2022Trial
- International real-world study of combination immunotherapy sequences in metastatic melanoma.Journal for immunotherapy of cancer · 2025Article
- The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma.American journal of clinical dermatology · 2025Review
- The progress and prospects of targeting the adenosine pathway in cancer immunotherapy.Biomarker research · 2025Review
- Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations.EJC skin cancer · 2025Article
- Engineered exosomes: a promising design platform for overcoming cancer therapy resistance.Frontiers in cell and developmental biology · 2025Review
- Overcoming Resistance Mechanisms to Melanoma Immunotherapy.American journal of clinical dermatology · 2025Review
- First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review.Biomolecules & biomedicine · 2024Review
- Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.Therapeutic advances in medical oncology · 2023Review
- Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma.Frontiers in oncology · 2023Article
Corrections and comments
- Comment on
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
35476655What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.